- Home
- OTLY vs NGNE Comparison
OTLY vs NGNE Comparison
Compare OTLY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- NGNE
- Stock Information
- Founded
- OTLY 1994
- NGNE 2003
- Country
- OTLY Sweden
- NGNE United States
- Employees
- OTLY N/A
- NGNE N/A
- Industry
- OTLY Packaged Foods
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- NGNE Health Care
- Exchange
- OTLY Nasdaq
- NGNE Nasdaq
- Market Cap
- OTLY 303.5M
- NGNE 251.9M
- IPO Year
- OTLY 2021
- NGNE N/A
- Fundamental
- Price
- OTLY $12.19
- NGNE $15.42
- Analyst Decision
- OTLY Buy
- NGNE Strong Buy
- Analyst Count
- OTLY 5
- NGNE 7
- Target Price
- OTLY $18.40
- NGNE $41.86
- AVG Volume (30 Days)
- OTLY 124.7K
- NGNE 193.9K
- Earning Date
- OTLY 07-23-2025
- NGNE 08-08-2025
- Dividend Yield
- OTLY N/A
- NGNE N/A
- EPS Growth
- OTLY N/A
- NGNE N/A
- EPS
- OTLY N/A
- NGNE N/A
- Revenue
- OTLY $822,041,000.00
- NGNE $925,000.00
- Revenue This Year
- OTLY $4.31
- NGNE N/A
- Revenue Next Year
- OTLY $5.01
- NGNE N/A
- P/E Ratio
- OTLY N/A
- NGNE N/A
- Revenue Growth
- OTLY 4.47
- NGNE N/A
- 52 Week Low
- OTLY $6.00
- NGNE $6.88
- 52 Week High
- OTLY $23.40
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- OTLY 54.80
- NGNE 40.98
- Support Level
- OTLY $11.84
- NGNE $19.13
- Resistance Level
- OTLY $13.26
- NGNE $18.21
- Average True Range (ATR)
- OTLY 0.70
- NGNE 1.59
- MACD
- OTLY -0.07
- NGNE -0.59
- Stochastic Oscillator
- OTLY 39.50
- NGNE 4.26
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.